Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Pharmacogenomics|April 10, 2002
Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profitsR Kerb, U BrinkmannPharmacogenomics|March 22, 2001
ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2R Kerb, S Hoffmeyer, U BrinkmannCancer Research|September 1, 1996
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer riskJ Brockmöller, I Cascorbi, R Kerb, et al.CPT: Pharmacometrics & Systems Pharmacology|July 31, 2014
Clinical translation in the virtual liver networkL Kuepfer, R Kerb, A M HenneyPharmacogenetics|April 20, 1999
Detection of the GSTM1*0 allele by long polymerase chain reactionR Kerb, J Brockmöller, C Sachse, et al.The Journal of Investigative Dermatology|February 1, 1997
Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivityR Kerb, J Brockmöller, T Reum, et al.Biochemical Pharmacology|February 4, 1992
Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reactionJ Brockmöller, D Gross, R Kerb, et al.Antimicrobial Agents and Chemotherapy|September 1, 1996
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericinR Kerb, J Brockmöller, B Staffeldt, et al.Cancer Research|August 1, 1994
Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control studyJ Brockmöller, R Kerb, N Drakoulis, et al.Toxicology Letters|February 18, 1999
Polymorphisms in xenobiotic conjugation and disease predispositionJ Brockmöller, I Cascorbi, R Kerb, et al.Pageof 3